Antitrust scrutiny of healthcare markets is nothing new. The Biden Administration and first Trump Administration focused antitrust enforcement efforts across the healthcare and life sciences industries. The newly installed...more
5/27/2025
/ Acquisitions ,
Antitrust Division ,
Antitrust Provisions ,
Chile ,
Competition ,
Corporate Practice of Medicine ,
Department of Justice (DOJ) ,
Deregulation ,
Enforcement Actions ,
EU ,
Healthcare ,
Healthcare Workers ,
Life Sciences ,
Mergers ,
Partnerships ,
Patents ,
Pharmaceutical Patents ,
South Africa ,
State Attorneys General ,
Teva Pharmaceuticals ,
Trump Administration
This year’s M&A Report offers a detailed review of the M&A market and outlook, including a breakdown by various geographies and industry sectors. We examine what might be in store with antitrust and CFIUS under the Trump...more
2/13/2025
/ Acquisitions ,
Antitrust Provisions ,
CFIUS ,
Cross-Border Transactions ,
Defense Strategies ,
Financial Services Industry ,
Information Reports ,
Initial Public Offering (IPO) ,
Merger Controls ,
Merger Reviews ,
Mergers ,
Premerger Notifications ,
Private Equity ,
Purchase Price ,
Purchase Price Adjustment ,
Venture Capital
With every change in administration, businesses and practitioners wonder what the new administration will mean for antitrust enforcement in the United States. Speculation was at fever pitch four years ago, after Democratic...more
2/13/2025
/ Acquisitions ,
Antitrust Division ,
Biden Administration ,
Competition ,
Corporate Counsel ,
Department of Justice (DOJ) ,
Enforcement Actions ,
Enforcement Priorities ,
Federal Trade Commission (FTC) ,
Hart-Scott-Rodino Act ,
Mergers ,
Trump Administration
This marks the second issue of WilmerHale’s The Interplay: Key Decisions at the Intersection of Antitrust & Life Sciences, a monthly bulletin that will highlight developments in the antitrust and life sciences space. We will...more
10/16/2023
/ Acquisitions ,
Criminal Prosecution ,
CVS ,
Department of Justice (DOJ) ,
Drug Pricing ,
False Marking ,
Federal Trade Commission (FTC) ,
Hatch-Waxman ,
Industry Consolidation ,
Life Sciences ,
Mergers ,
Orange Book ,
Partnerships ,
Pharmaceutical Industry ,
Pharmacies ,
Policy Statement ,
Section 340B ,
TPAs